BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 28296140)

  • 1. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
    Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
    Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S; Tang Y; Yan M; Jiang W
    Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
    Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
    Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
    Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
    Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
    Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
    Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
    Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
    Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.